CCM
SCMP

Cadence Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Cadence Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-83,021
Closed -$1.49M – 721
2017
Q4 		$1.49M Buy
83,021
+26,973
+48% +$332K 0.09% 287
2017
Q3 		$661K Buy
+56,048
New +$629K 0.04% 454
2017
Q2 		– Sell
-80,482
Closed -$885K – 717
2017
Q1 		$885K Sell
80,482
-36,441
-31% -$423K 0.06% 385
2016
Q4 		$1.58M Buy
116,923
+29,249
+33% +$408K 0.11% 229
2016
Q3 		$1.08M Buy
87,674
+63,795
+267% +$752K 0.08% 291
2016
Q2 		$262K Sell
23,879
-411
-2% -$4.6K 0.02% 541
2016
Q1 		$265K Hold
24,290
– – 0.02% 567
2015
Q4 		$420K Sell
24,290
-1,693
-7% -$30.4K 0.03% 495
2015
Q3 		$516K Buy
+25,983
New +$596K 0.04% 445
2014
Q4 		– Sell
-152,632
Closed -$992K – 685
2014
Q3 		$992K Sell
152,632
-4,210
-3% -$28K 0.05% 412
2014
Q2 		$1.08M Sell
156,842
-17,303
-10% -$122K 0.05% 412
2014
Q1 		$1.25M Buy
174,145
+29,840
+21% +$255K 0.05% 403
2013
Q4 		$1.36M Sell
144,305
-13,860
-9% -$98.9K 0.05% 364
2013
Q3 		$987K Buy
158,165
+82,575
+109% +$516K 0.03% 441
2013
Q2 		$497K Buy
+75,590
New +$600K 0.02% 348

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Cadence Capital Management's SCMP Position: Q1 2018 in Review

Cadence Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 83,021 shares — an estimated $1.49M sold.

Cadence Capital Management first reported a position in SCMP in Q2 2013 and held it in 15 quarters. The position peaked at $1.58M in Q4 2016. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Cadence Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cadence Capital Management sold 83,021 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.49M.
  • Cadence Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Cadence Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.58M in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Cadence Capital Management's 13F filing for Q1 2018, filed 14 May 2018.